Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2/3 signaling, is now FDA approved for the treatment of very low to intermediate risk MDS with ring sideroblasts and SF3B1 mutation. This evidence concerns the gene SMAD2 and myelodysplastic syndrome.